Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease

• US 7,674,783 B2
• Filed: 10/21/2003
• Issued: 03/09/2010
• Est. Priority Date: 11/22/2002
• Status: Expired due to Fees

• Current Assignee: Dimera Incorporated
• Original Assignee: Dimera Incorporated
• Inventors: Hermsmeyer, R. Kent
• Primary Examiner(s): Padmanabhan; Sreeni
• Assistant Examiner(s): Ramachandran; Umamaheswari
• Application Number:
  US10/690,169
• Publication Number:
  US 20040102427A1
• Time in Patent Office: 2,331 Days
• Field of Search: 514/178, 514/177, 514/182
• US Class Current: 514/178
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/26 Androgens
• CPC Class Codes: A61P 5/30 Oestrogens
• CPC Class Codes: A61P 5/34 Gestagens
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

A method for preventing or treating vascular hyperreactivity in which a chemical compound that is an estrogen beta receptor agonist is administered to a subject suffering from or at risk of vascular hyperreactivity. Preferably, the administration is topically to the skin.

Claims

1. A method for reducing vascular hyperreactivity in vascular muscle cells comprising exposing the vascular muscle cells to an effective amount of a selective estrogen beta receptor agonist that is selected from the group consisting of 5α

-androstane-3β

,17β

-diol, a derivative of 5α

-androstane-3β

,17β

-diol that has estrogen beta receptor agonist activity, epiestriol, and diarylpropionitrile.

2. The method of claim 1 wherein the vascular hyperreactivity is manifested by coronary arterial vasospasm.

3. The method of claim 1 wherein the vascular hyperreactivity is manifested by hyperreactivity of peripheral arteries.

4. The method of claim 1 wherein the estrogen beta receptor agonist is 5α

-androstane-3β

,17β

-diol.

5. The method of claim 1 wherein the estrogen beta receptor agonist is a derivative of 5α

-androstane-3β

,17β

-diol that has estrogen beta receptor agonist activity.

6. The method of claim 5 wherein the derivative of 5α

-androstane-3β

,17β

-diol is selected from the group consisting of 5α

-androstane-3β

,17β

-diol-3 hemisuccinate, 5α

-androstane-3β

-diol-17-sulphate sodium salt, 5α

-androstan-3β

,17β

-diol-3-acetate, 5α

-androstan-3β

,17β

-diol-17-acetate, 5α

-androstan-3β

,17β

-diol-diacetate, 5α

-androstan-3β

,17β

-diol-dibenzoate, 5α

-androstan-3β

,17β

-diol-dihemisuccinate, 5α

-androstan-3β

,17β

-diol-diproprionate, and 5α

-androstan-3β

,17β

-diol-17-hexahydrobenzoate.

7. The method of claim 1 wherein the estrogen beta receptor agonist is epiestriol.

8. The method of claim 1 wherein the estrogen beta receptor agonist is diarylpropionitrile.

9. The method of claim 4 wherein the 5α

-androstane-3β

,17β

-diol is administered to a patient and the amount of 5α

-androstane-3β

,17β

-diol that is administered is sufficient to obtain a serum concentration of between 30 and 3000 pg/ml.

10. The method of claim 9 wherein the amount of 5α

-androstane-3β

,17β

-diol that is administered is sufficient to obtain a serum concentration of between 30 and 300 pg/ml.

11. The method of claim 1 wherein the estrogen beta receptor agonist is administered to a patient in concert with a hormone replacement therapy.

12. The method of claim 11 wherein the hormone replacement therapy is selected from the group consisting of estrogen, androgen, and progestin therapy.

13. The method of claim 1 wherein the exposure of the vascular muscle cells to the estrogen beta receptor agonist is by administering the estrogen beta receptor agonist by topical application to skin of a patient.

14. The method of claim 13 wherein the estrogen beta receptor agonist is in a topical preparation selected from the group consisting of a liquid, cream, gel, lotion, ointment, and transdermal patch.

15. The method of claim 1 wherein the exposure of the vascular muscle cells to the estrogen beta receptor agonist is by other than topical administration to skin.

16. The method of claim 15 wherein the exposure is by oral, rectal, vaginal, topical, sublingual, nasal, intradermal, inhalation, or sustained implant administration routes.